AOD-9604

AOD-9604 (anti-obesity drug 9604; Tyr-hGH(177–191)) is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic fragment of human growth hormone, modified with an N-terminal tyrosine residue for stability, and investigated as a candidate anti-obesity compound on the premise that the lipolytic activity of hGH resides in this C-terminal domain — separable from the growth-promoting and insulin-antagonizing effects mediated by other regions of the full-length molecule. AOD-9604 is proposed to stimulate fat metabolism through beta-3 adrenergic receptor-mediated pathways without activating IGF-1 production or the anabolic receptor domains of full-length GH, making it theoretically safer than GH itself for metabolic applications; a 2001 preclinical study in obese mice (PMID 11713213) demonstrated lipolytic effects and body weight reduction via this mechanism. Clinical trials were conducted in humans by Metabolic Pharmaceuticals, and Phase 2/3 data generated in Australia suggested modest weight loss effects; however, the primary trial results were never published in PubMed-indexed peer-reviewed journals, and the best indexed primary evidence for AOD-9604 remains that preclinical mouse study. AOD-9604 has no FDA approval and no approved indication in any jurisdiction; despite its human clinical program, the absence of published peer-reviewed primary trial data means clinical efficacy and safety cannot be independently evaluated, and no validated human dosing protocol has been established. The compound is currently available only as a research peptide. AOD-9604 is supplied as a lyophilized powder for research use; oral formulations were also evaluated in the clinical program as an alternative to subcutaneous delivery, though no commercial oral AOD-9604 product reached market. AOD-9604 evidence limitations The primary indexed evidence base for AOD-9604 consists of a 2001 preclinical study in obese mice (PMID 11713213) demonstrating beta-3 adrenergic receptor-mediated lipolysis and body weight reduction without IGF-1 elevation or blood glucose disruption. The Phase 2/3 human clinical program conducted by Metabolic Pharmaceuticals generated obesity trial data, but those primary results were never published in PubMed-indexed peer-reviewed journals, meaning the human efficacy and safety dataset cannot be independently evaluated. No validated human dosing protocol has been established for AOD-9604 in any jurisdiction, and no approved clinical indication exists. The absence of published human trial data represents a fundamental gap that precludes definitive statements about clinical efficacy, optimal administration, or long-term safety. AOD-9604 side effects and safety profile The safety data from AOD-9604's clinical program includes several notable findings: no elevation in IGF-1 levels was observed at studied doses — a key distinction from full-length growth hormone, where IGF-1 elevation drives concerns about cell proliferation and potential oncogenicity. No significant disruption of fasting glucose or insulin sensitivity was documented. No serious adverse events attributable to AOD-9604 were reported in published trial summaries. The absence of anabolic receptor activity (no binding to the GH receptor growth-promoting domain) is the proposed basis for this benign safety profile compared to GH itself. Long-term safety data does not exist due to the absence of Phase 3 completion and product approval. Research-grade AOD-9604 carries standard purity and contamination risks associated with unregulated compounding. Providers offering AOD-9604 through supervised clinical programs are searchable in the PeptideBase provider directory.